CD30-positive lymphoma

April 23, 2019

Epstein-Barr Vaccination Could Cut Risk of B-cell Lymphoma, Study Suggests

News

Chronic B-cell activation — which can happen because of infectious mononucleosis, commonly caused by the Epstein-Barr virus (EBV) — triggers an excessive proliferation of certain B cells, which can evolve into a B-cell lymphoma. Although ... Read more

February 5, 2018February 5, 2018

Affimed’s AFM13 Shows High Response Rates in 2 Lymphoma Subtypes

News

AFM13, a bispecific antibody that recruits natural killer (NK) cells to the vicinity of a tumor, has shown promise in clinical trials of both Hodgkin’s lymphoma and in CD30-positive cutaneous ... Read more

June 21, 2017

Seattle Genetics Asks FDA to Approve Adcetris for Expanded Set of Lymphoma Patients

News

Seattle Genetics is asking the U.S. Food and Drug Administration to approve Adcetris (brentuximab vedotin) for an expanded set of cutaneous T-cell lymphoma patients. The agency has yet to authorize Adcetris for CTCL. A supplemental Biologics ... Read more

June 13, 2017June 13, 2017

Adcetris Shows Promise in Phase 3 Trial to Treat Certain Cutaneous T-Cell Lymphoma Patients

News

The investigational therapy Adcetris (brentuximab vedotin) shows promise as a potential treatment for patients with cutaneous T-cell lymphoma (CTCL), according to results of a Phase 3 clinical trial. Findings were published in ... Read more